|
|
Blood, 1 May 2004, Vol. 103, No. 9, pp. 3603-3605.
Prepublished online as a Blood First Edition Paper on January 8, 2004; DOI 10.1182/blood-2003-10-3479.

Submitted October 17, 2003
Accepted December 20, 2003
Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem-cell transplantation
Alexander Woywodt*, Johanna Scheer, Lothar Hambach, Stefanie Buchholz, Arnold Ganser, Hermann Haller, Bernd Hertenstein, and Marion Haubitz
Division of Nephrology, Hannover Medical School, Hannover, Germany
Division of Nephrology, Hannover Medical School, Hannover, Germany; Division of Haematology/Oncology/Haemostaseology, Hannover Medical School, Hannover, Germany
Division of Haematology/Oncology/Haemostaseology, Hannover Medical School, Hannover, Germany
* Corresponding author; email: Woywodt.Alexander{at}mh-hannover.
Damage to endothelial cells is the common feature of vascular disorders associated with hematopoietic stem-cell transplantation (HSCT). Elevated numbers of circulating endothelial cells reflect the extent of endothelial damage in a variety of disorders but their use in HSCT has not been investigated so far. We studied 39 patients undergoing allogeneic HSCT with different conditioning regimens and 22 healthy controls. Circulating endothelial cells were enumerated with immunomagnetic isolation during the course of HSCT. After conditioning, cell numbers were significantly elevated (median 44 cells/ml) compared to baseline (median 16 cells/ml) and controls (median 8 cells/ml). Patients who received radiation had an earlier peak when compared to patients with chemotherapy. Patients with reduced intensity conditioning had significantly lower cell numbers (median 24 cells/ml) than those who received standard conditioning. These observations provide a novel marker to investigate microvascular endothelial damage and the effects of different conditioning regimens in patients undergoing HSCT.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Woywodt, T. Kirsch, and M. Haubitz
Circulating endothelial cells in renal disease: markers and mediators of vascular damage
Nephrol. Dial. Transplant.,
January 1, 2008;
23(1):
7 - 10.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Murata, A. Janin, C. Leboeuf, J. Soulier, E. Gluckman, V. Meignin, and G. Socie
Donor-derived cells and human graft-versus-host disease of the skin
Blood,
March 15, 2007;
109(6):
2663 - 2665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Eissner, J. Wiesner, N. Hahn, M. Iacobelli, M. Haubitz, R. Andreesen, and E. Holler
In Vitro Monitoring of Defibrotide Prophylaxis for Endothelial Complications Following Allogeneic Stem Cell Transplantation.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
2969 - 2969.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Boos, G. Y.H. Lip, and A. D. Blann
Circulating Endothelial Cells in Cardiovascular Disease
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1538 - 1547.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. M. Rigolin, C. Fraulini, M. Ciccone, E. Mauro, A. M. Bugli, C. De Angeli, M. Negrini, A. Cuneo, and G. Castoldi
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
Blood,
March 15, 2006;
107(6):
2531 - 2535.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al.
Circulating Endothelial Cells in Venous Blood as a Marker of Endothelial Damage in Chronic Venous Insufficiency: Improvement with Venoruton
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2006;
11(1):
93 - 99.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A Woywodt, C Goldberg, T Kirsch, K de Groot, U Erdbruegger, H Haller, and M Haubitz
Circulating endothelial cells in relapse and limited granulomatous disease due to ANCA associated vasculitis
Ann Rheum Dis,
February 1, 2006;
65(2):
164 - 168.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al.
Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Clin. Cancer Res.,
September 15, 2005;
11(18):
6615 - 6624.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|